repaglinide [orch, phsu]
pharmacoeconomic [qnco]
Type 2 Diabetes [dsyn]
repaglinide [orch, phsu]
R- [spco]
NovoNorm [orch, phsu]
R- [spco]
GlucoNorm [orch, phsu]
R- [spco]
Oral [spco]
Insulin [aapp, horm, phsu]
Meglitinide [orch, phsu]
Analog [chvs]
Available [ftcn]
Patients [podg]
Diabetes Mellitus, Type 2 [dsyn]
Drug [phsu]
Postprandial [tmco]
Glucose [bacs, carb, phsu]
Targeting [ftcn]
Phase [tmco]
Insulin [aapp, horm, phsu]
Release [hlca]
Thought [menp]
Reducing [qlco]
cardiovascular complications [patf]
Diabetes [dsyn]
repaglinide [orch, phsu]
Provided [acty]
glycemia [carb]
Glibenclamide [orch, phsu]
Glyburide [orch, phsu]
Assessed [acty]
Glycosylated haemoglobin [aapp, bacs]
HbA [aapp, bacs]
Fasting blood glucose level [lbpr]
Well [qlco]
Design [acty]
Clinical Trials [resa]
Rapid onset [fndg]
Short duration [qlco]
Action [ftcn]
Flexible [qlco]
Meal [dora]
Schedules [inpr]
Cost Effectiveness Analysis [ocac]
Projected [inpr]
Costs [qnco]
Patients [podg]
Type 2 Diabetes [dsyn]
Projected [inpr]
Complications [patf]
HbA [aapp, bacs]
Short-term [tmco]
Clinical Trials [resa]
repaglinide [orch, phsu]
rosiglitazone [orch, phsu]
Dominant [ftcn]
rosiglitazone [orch, phsu]
repaglinide [orch, phsu]
Plus [qlco]
Metformin [orch, phsu]
Dominant [ftcn]
nateglinide [aapp, phsu]
Plus [qlco]
Metformin [orch, phsu]
canadian [fndg]
Favorable [qlco]
Incremental [qnco]
Cost Effectiveness [qnco]
Ratio [qnco]
QALY [tmco]
Gain [qnco]
Values [qlco]
Patients [podg]
Switch [mnob]
Sulfonylurea [orch, phsu]
repaglinide [orch, phsu]
Sulfonylurea [orch, phsu]
therapy [ftcn]
Projected [inpr]
Short-term [tmco]
Clinical Data [inpr]
Trial [resa]
Postprandial [tmco]
Blood glucose level [lbtr]
canadian [fndg]
Study [mnob]
Cost Effectiveness Analysis [ocac]
Available [ftcn]
Abstracts [inpr]
Posters [inpr]
Cost Analyses [ocac]
Published [ocac]
Full [qlco]
Conduct [inbe]
Short-term [tmco]
Costs [qnco]
repaglinide [orch, phsu]
Metformin [orch, phsu]
Oral [spco]
antidiabetic [phsu]
regimens [inpr]
Somewhat [inpr]
Equivocal [qlco]
Study Design [resa]
Issue [fndg]
lack [qlco]
statistically significant [qnco]
treatment [ftcn]
Group [idcn]
repaglinide [orch, phsu]
Combination [qlco]
Antidiabetic Agents [phsu]
Metformin [orch, phsu]
rosiglitazone [orch, phsu]
Good [qlco]
Metabolic Control [moft]
Glibenclamide [orch, phsu]
regimens [inpr]
Severe [qlco]
Hypoglycemic episodes [dsyn]
repaglinide [orch, phsu]
Including [ftcn]
Glibenclamide [orch, phsu]
Cost Effectiveness Analysis [ocac]
Conduct [inbe]
North America [geoa]
Favorable [qlco]
repaglinide [orch, phsu]
Containing [ftcn]
regimens [inpr]
Comparator [mnob]
Attribute [idcn]
Projected [inpr]
reductions [npop]
cardiovascular complications [patf]
Short-term [tmco]
glycemia [carb]
Parameters [fndg]
Clinical Trials [resa]
Cost Effectiveness Analysis [ocac]
Published [ocac]
Abstracts [inpr]
Posters [inpr]
interpreted [ftcn]
Various [irda]
Costs [qnco]
Models, Economic [inpr, qnco]
repaglinide [orch, phsu]
Addition [ftcn]
Available [ftcn]
treatment options [topp]
Type 2 Diabetes [dsyn]
Agent [chvf]
Reducing [qlco]
cardiovascular complications [patf]
confirmation [qlco]
Diabetes Mellitus [dsyn]
Projected [inpr]
World [popg]
Million [qnco]
People [popg]
Patients [podg]
Diabetes [dsyn]
type disease [inpr]
Countries [geoa]
Proportion [qnco]
type disease [inpr]
>90 [qnco]
Estimated [qnco]
Million [qnco]
Million [qnco]
Diagnosed [fndg]
Type 2 Diabetes [dsyn]
Addition [ftcn]
Approximately [qlco]
Half [qnco]
Diabetes [dsyn]
unaware [resa]
Diabetes [dsyn]
Morbidity [qnco]
Mortality [qnco]
Economic [ocdi]
consequences [ftcn]
Direct Costs [qnco]
Medical [ftcn]
Diabetes [dsyn]
Type I [clas]
Estimated [qnco]
Cost [qnco]
Indirect Costs [qnco]
Patients [podg]
Eight [qnco]
European country [geoa]
Cost [qnco]
Diabetes [dsyn]
Annually [tmco]
Values [qlco]
Proportion [qnco]
Health Care [hlca]
Expenditure [qnco]
Direct [qlco]
Diabetes [dsyn]
Range [qnco]
depend [medd]
Country [geoa]
Several [qnco]
focusing [clna]
type disease [inpr]
Costs [qnco]
Patients [podg]
Diabetic Complications [patf]
Without [qlco]
Complications [patf]
repaglinide [orch, phsu]
Meglitinide [orch, phsu]
Analog [chvs]
Oral [spco]
Insulin [aapp, horm, phsu]
Postprandial [tmco]
Glucose [bacs, carb, phsu]
Targeting [ftcn]
Postprandial [tmco]
Insulin [aapp, horm, phsu]
Release [hlca]
Clinical Trials [resa]
Patients [podg]
Type 2 Diabetes [dsyn]
repaglinide [orch, phsu]
Administered [ftcn]
Dosage [qnco]
Three times daily [tmco]
Meals [dora]
Combination [qlco]
Agent [chvf]
placebo-controlled [resa]
Trial [resa]
weeks [tmco]
Duration [tmco]
Patients [podg]
Type 2 Diabetes [dsyn]
repaglinide [orch, phsu]
statistically significant [qnco]
Improvement [cnce]
glycemia [carb]
Assessed [acty]
Glycosylated haemoglobin [aapp, bacs]
HbA [aapp, bacs]
Fasting blood glucose [lbpr]
Postprandial [tmco]
blood glucose levels [lbtr]
Compared [acty]
placebo [topp]
Preprandial [tmco]
Administration [ocac]
repaglinide [orch, phsu]
glycemia [carb]
Glibenclamide [orch, phsu]
Glyburide [orch, phsu]
1 Day [tmco]
mg% [qnco]
glycemia [carb]
Glipizide 5 MG [clnd]
DOUBLE BLIND [resa]
Trial [resa]
Patients [podg]
type disease [inpr]
majority [socb]
Received [qlco]
Oral [spco]
antidiabetic [phsu]
therapy [ftcn]
Several [qnco]
Open Label Study [resa]
Evaluated [ftcn]
repaglinide [orch, phsu]
Part [spco]
Combination Therapy [topp]
3 Months [tmco]
Patients [podg]
Type 2 Diabetes [dsyn]
Inadequate [qlco]
glycemia [carb]
Previous [tmco]
Drug Therapy [topp]
General [spco]
statistically significant [qnco]
Improvement [cnce]
glycemia [carb]
Combination [qlco]
Metformin [orch, phsu]
Various [irda]
Thiazolidinediones [orch, phsu]
Metformin [orch, phsu]
Plus [qlco]
Bedtime [tmco]
Insulin [aapp, horm, phsu]
Compared [acty]
Comparator [mnob]
Drug [phsu]
Study [mnob]
Metformin [orch, phsu]
Plus [qlco]
Bedtime [tmco]
Insulin [aapp, horm, phsu]
Trial [resa]
METFORMIN/REPAGLINIDE [orch, phsu]
Plus [qlco]
glycemia [carb]
Metformin [orch, phsu]
Plus [qlco]
nateglinide [aapp, phsu]
Three times daily [tmco]
weeks [tmco]
glycemia [carb]
Metformin [orch, phsu]
Combination [qlco]
Glibenclamide [orch, phsu]
glimepiride [orch, phsu]
Good [qlco]
glycemia [carb]
Preprandial [tmco]
Administration [ocac]
repaglinide [orch, phsu]
Flexible [qlco]
Meal [dora]
Schedules [inpr]
placebo-controlled [resa]
Trial [resa]
Large [qnco]
prospective [resa]
Survey [inpr]
Patients [podg]
Receive [qlco]
repaglinide [orch, phsu]
Clinical setting [spco]
TOLERABILITY [resa]
Profile [lbpr]
repaglinide [orch, phsu]
adverse events [fndg]
Mild to moderate [qlco]
Intensity [qlco]
sulphonylureas [orch, phsu]
Frequently [tmco]
Reported [inpr]
adverse events [fndg]
repaglinide [orch, phsu]
Hypoglycaemia [dsyn]
Upper respiratory infection [dsyn]
Headache [sosy]
Respiratory event [fndg]
Musculoskeletal [ftcn]
Events [evnt]
gastrointestinal [spco]
Events [evnt]
Severe [qlco]
Episodes [tmco]
Hypoglycaemia [dsyn]
Rare [tmco]
repaglinide [orch, phsu]
Approximately [qlco]
times [tmco]
Frequently [tmco]
sulphonylureas [orch, phsu]
Addition [ftcn]
Available [ftcn]
repaglinide [orch, phsu]
Likely [qlco]
Body Weight [orga]
Various [irda]
Sulfonylurea [orch, phsu]
Agent [chvf]
General [spco]
repaglinide [orch, phsu]
Well [qlco]
Part [spco]
Combination Therapy [topp]
repaglinide [orch, phsu]
Cytochrome P-450 Enzyme System [aapp, enzy]
Substrate [mnob]
Administered [ftcn]
Healthy Volunteers [popg]
PHARMACOKINETIC DRUG INTERACTIONS [rnlw]
Administered [ftcn]
Digoxin [carb, phsu, strd]
Theophylline [bacs, orch, phsu]
Warfarin [hops, orch, phsu]
Cimetidine [orch, phsu]
Ketoconazole [orch, phsu]
Rifampicin [antb, orch]
Rifampin [antb, orch]
Ethinyl Estradiol [horm, phsu, strd]
Simvastatin [orch, phsu]
Nifedipine [orch, phsu]
Systemic [ftcn]
Exposure NOS [inpo]
repaglinide [orch, phsu]
Clarithromycin [antb, orch]
repaglinide [orch, phsu]
Administered [ftcn]
reduction [npop]
repaglinide [orch, phsu]
Dosage [qnco]
Hazard [qlco]
Interaction [ftcn]
Gemfibrosil [lipd, phsu]
Alone [qnco]
ZOLE [opco, phsu]
repaglinide [orch, phsu]
Marked [qlco]
Systemic [ftcn]
Exposure NOS [inpo]
repaglinide [orch, phsu]
Combination [qlco]
repaglinide [orch, phsu]
Gemfibrosil [lipd, phsu]
If [qlco]
Cost Analyses [ocac]
Conduct [inbe]
repaglinide [orch, phsu]
Patients [podg]
Type 2 Diabetes [dsyn]
Published [ocac]
Full [qlco]
retrospective [resa]
Pharmacy [hcro]
Medical [ftcn]
Large [qnco]
Managed Care Organization [hcro, mnob]
Cost [qnco]
Adjusted [ftcn]
Age [orga]
Gender [orga]
Comorbidities [idcn]
Adjusted [ftcn]
Cost [qnco]
treated [topp]
Combination [qlco]
repaglinide [orch, phsu]
Plus [qlco]
Metformin [orch, phsu]
Patients [podg]
Received [qlco]
Metformin [orch, phsu]
Metformin [orch, phsu]
Plus [qlco]
Glibenclamide [orch, phsu]
repaglinide [orch, phsu]
statistically significant [qnco]
treatment [ftcn]
Group [idcn]
Study [mnob]
Literature [inpr]
Based [ftcn]
Decision Analysis [ocdi]
Tree [plnt]
Projected [inpr]
Proportion [qnco]
Patients [podg]
Target [ftcn]
HbA [aapp, bacs]
Direct Costs [qnco]
Medical [ftcn]
Six [qnco]
Treatment Regimen [topp]
Evaluated [ftcn]
Costs [qnco]
Range [qnco]
Glipizide [orch, phsu]
Gastrointestinal system [bdsy]
Therapeutic [topp]
repaglinide [orch, phsu]
Values [qlco]
Sensitivity [qnco]
Indicated [fndg]
First-Line Therapy [topp]
Glipizide [orch, phsu]
Gastrointestinal system [bdsy]
Therapeutic [topp]
Metformin [orch, phsu]
Medical [ftcn]
Costs [qnco]
rosiglitazone [orch, phsu]
repaglinide [orch, phsu]
Cost Effectiveness Analysis [ocac]
Published [ocac]
Abstracts [inpr]
Posters [inpr]
Conduct [inbe]
repaglinide [orch, phsu]
Patients [podg]
Type 2 Diabetes [dsyn]
Conduct [inbe]
Medicare [gora]
Combination Therapy [topp]
Including [ftcn]
repaglinide [orch, phsu]
Dominant [ftcn]
treatment [ftcn]
strategy [menp]
Comparator [mnob]
regimens [inpr]
Compared [acty]
repaglinide [orch, phsu]
Plus [qlco]
rosiglitazone [orch, phsu]
rosiglitazone [orch, phsu]
Compared [acty]
repaglinide [orch, phsu]
Plus [qlco]
Metformin [orch, phsu]
nateglinide [aapp, phsu]
Plus [qlco]
Metformin [orch, phsu]
Projected [inpr]
Costs [qnco]
qalys [tmco]
discount [inpr]
Annual [tmco]
Complications [patf]
Projected [inpr]
HbA [aapp, bacs]
Short-term [tmco]
Clinical Trials [resa]
Conduct [inbe]
Canada [geoa]
Third Party Payer [hcro]
Favorable [qlco]
Incremental [qnco]
Cost Effectiveness [qnco]
Ratio [qnco]
QALY [tmco]
Gain [qnco]
Values [qlco]
Patients [podg]
Switch [mnob]
Sulfonylurea [orch, phsu]
repaglinide [orch, phsu]
Sulfonylurea [orch, phsu]
therapy [ftcn]
Study [mnob]
discount rate [qnco]
Annually [tmco]
Complications [patf]
Projected [inpr]
Short-term [tmco]
Clinical Data [inpr]
Trial [resa]
Postprandial [tmco]
blood glucose levels [lbtr]
Cost Effectiveness Analysis [ocac]
Attribute [idcn]
Favorable [qlco]
repaglinide [orch, phsu]
Containing [ftcn]
regimens [inpr]
Projected [inpr]
reductions [npop]
cardiovascular complications [patf]
Degree [qlco]
interpreting [ftcn]
economic analysis [ocac]
repaglinide [orch, phsu]
Cost Effectiveness Analysis [ocac]
Published [ocac]
Aspect [qnco]
Study [mnob]
methodology [inpr]
Not available [idcn]
Cost Effectiveness Analysis [ocac]
General [spco]
Always [tmco]
Degree [qlco]
Uncertainty [idcn]
Project [cnce]
Costs [qnco]
Short-term [tmco]
Clinical Data [inpr]
Trial [resa]
Addition [ftcn]
Conduct [inbe]
Canada [geoa]
Favorable [qlco]
repaglinide [orch, phsu]
Containing [ftcn]
regimens [inpr]
Observed [ftcn]
North American [fndg]
Apply [hlca]
Europe [geoa]
economic analysis [ocac]
repaglinide [orch, phsu]
APPEAR [qlco]
Well [qlco]
Accepted [qlco]
Study [mnob]
Methods [inpr]
Example [cnce]
absence [qnco]
prospective [resa]
CARDIOVASCULAR [bdsy]
Diabetic Complications [patf]
repaglinide [orch, phsu]
Antidiabetic Agents [phsu]
Standard [qlco]
Modeling [inpr, resa]
techniques [inpr]
